2026年7月15日，同源康医药-B（02410）公布2026年第一次临时股东大会投票结果。会上，公司就“发行股份的发行授权”提出的特别决议案获得135,580,001票赞成，占有效表决权的93.58%；反对票4,625,576票，占3.19%；弃权票4,681,502票，占3.23%。由于赞成票比例超过三分之二，相关决议正式获股东通过。
截至会议当日，公司已发行股份总数为380,065,818股。受股权激励计划影响，受托人所持1,480,500股股份不具投票权，可参与表决的股份总数为378,585,318股。股东及其代表实际出席并行使表决权的股份为144,887,079股，占已发行股份总数约38.12%。
本次会议的召集、召开及表决程序均符合中国公司法及公司章程的相关规定，香港中央证券登记有限公司担任监票机构。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.